Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
- GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer March 13, 2026
MDNA113 a Potentially Groundbreaking Immune Therapy for Solid Tumors Including mCRPC
/in Immunotherapy, Preclinical Research/by MaxAlphaGenome: Another Incredible AI Tool for Biology
/in Artificial Intelligence/by MaxPhase 1 Trial of 225Ac-ETN029 for Neuroendocrine Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Trial: WGc-043, Exploring a New mRNA Vaccine for EBV-Positive Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxPhase 1 Results for Imaging Agent Cu-61 NuriPro Shows Promise for Future Theranostic Option Cu-67
/in Clinical Trial, Metastatic, Phase 1/by MaxAt the 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) annual meeting, a promising phase I clinical trial results were presented for Cu-61 NuriPro, a next-generation PET imaging agent specifically designed for patients with PSMA-positive metastatic prostate cancer. This agent targets prostate-specific membrane antigen (PSMA), a protein commonly overexpressed in prostate cancer cells, making […]
Phase 1 Results for 225Ac-LNC1011, a Novel Alpha Emitter Therapy for mCRPC
/in Clinical Trial, Metastatic, Phase 1/by MaxDiWB-1: A Targeted Approach to Prostate Cancer Treatment
/in Pepetide-Drug Conjugate, Preclinical Research/by MaxDiWB-1, a luteinizing hormone-releasing hormone (LHRH)-targeted peptide-drug conjugate (PDC) with PI3K inhibition properties, is an emerging candidate that may offer a new way to treat prostate cancer. Its design and mechanism suggest potential for addressing some of the limitations of current treatments, particularly for resistant cases. DiWB-1 is described as an LHRH-targeted PDC, a class […]
New Method Uses Nanoparticles to Create CAR T Cells Inside Body for Cancer Treatment
/in mRNA, Preclinical Research/by Max